Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.48 (market cap $29.60B), while Direxion Daily TSLA Bull 2X Shares trades at $8.05. Which is the better fit depends on your goals.
| ALNY | TSLL | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $23.03 |
52-Week Low | $205.48 | $6.74 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, is trading at $7.975, down 2.86% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The ETF aims to deliver twice Tesla's daily returns, amplifying volatility in a stock known for significant price swings. Recent news highlights its sensitivity to Tesla's performance, with Q2 earnings on July 22, 2026, potentially driving sharp moves.
The outlook for TSLL is highly speculative, tied directly to Tesla's stock volatility, offering leveraged upside but with elevated risk of losses even in rising markets. Investors face risks from daily rebalancing decay, market sentiment shifts, and Tesla-specific developments, requiring caution due to the ETF's non-traditional structure and lack of fundamental company metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
